Fusion peptides as antimicrobial agents
US12098217B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Jan 17, 2020 |
| Grant date | Sep 24, 2024 |
| Priority date | — |
| Expiry date | Jul 10, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/10
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
The present invention relates to a fusion peptide having one of the following formulae: P1-L-P2 (I) or P2-L-P1 (II) wherein P1 is chosen from the proline-rich antimicrobial peptides; Lisa peptide linker; and P2 has the following formula (III): wherein m is 0 or 1; n is an integer comprised between 0 and 9; p is an integer comprised between 0 and 10; r is 0, 1 or 2; s is 0 or 1; Gln is glutamine; R1 is the side chain of arginine or lysine; R2 is for example a —(CH2)—C3-6-cycloalkyl group optionally substituted; R3 is for example a C1-8-alkyl group; R4 is in particular a C1-8-alkyl group optionally substituted by a C3-6-cycloalkyl group; R5 is for example a —(CH2)—C3-6-cycloalkyl group; R6 is in particular —COOH, wherein, when the fusion peptide has the formula (II), its C-terminus contains a —CO— group engaged in a peptide bond with said linker.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.